Remifemin is a uniquely formulated nutritional supplement derived from black cohosh (Cimicifuga racemosa) root and rhizome. The effectiveness of Remifemin in the management of menopausal...
Remifemin is a uniquely formulated nutritional supplement derived from black cohosh (Cimicifuga racemosa) root and rhizome. The effectiveness of Remifemin in the management of menopausal symptoms has been established from rigorous, well-controlled, clinical trials as well as open clinical monitoring trials in physicians' practices studying over 1200 women in total. The findings prove that Remifemin safely and effectively reduces hot flashes, night sweats, related occasional sleeplessness, irritability, and mood swings associated with menopause. The standardized black cohosh extract in Remifemin is: Backed by nearly 50 years of clinical studies. Proven to be effective, safe, and well tolerated. Rated number one in recommended non-prescription menopausal therapies by obstetricians and gynecologists. Clinically proven to reduce hot flashes, night sweats, related occasional sleeplessness, irritability, and mood swings associated with menopause. How Does It Work? Menopause is the transition period in a woman's life when her ovaries stop producing eggs, her body produces less estrogen and progesterone, and menstruation becomes less frequent, eventually stopping altogether. One of estrogen's many functions is the suppression of a substance called luteinizing hormone (LH). As estrogen levels decline during menopause, high levels of LH are found in the bloodstream. Hot flashes and night sweats, the most commonly experienced menopausal symptoms, may be linked to high levels of this hormone. Hot flashes (also referred to as hot flushes) are a sudden sensation of heat often accompanied by facial flushing and sweating that generally lasts a few seconds to a few minutes. When hot flashes occur during sleep they are referred to as night sweats. Their presence often leads to occasional sleeplessness, irritability, and mood swings. Some women experience few symptoms, while others experience various symptoms ranging from mild to fairly severe. This variation is normal and expected. Until July of 2002, hormone replacement therapy (HRT) was the most common treatment to relieve the discomforts of menopause. Since that time, repeated findings from clinical research have concluded that, for most women, the harmful effects of estrogen and progestin are likely to exceed the benefits. Health organizations world wide are strongly encouraging women with a personal or family history of heart disease, blood clots, and breast cancer not use HRT for menopausal symptom relief. Research to date suggests that black cohosh has no estrogenic activity. No significant adverse effects have reported in clinical trials. It has been determined safe for use by women who have had breast cancer who cannot take estrogen. Several European studies indicate that black cohosh, specifically Remifemin, may be as effective as hormone replacement therapy (HRT) in reducing hot flashes, night sweats, related occasional sleeplessness, irritability, and mood swings associated with menopause.As Remifemin does not exert an estrogenic effect on breast tissue, it is suggested that it can be safely used by women with a history of breast cancer who cannot take estrogen. Clinical Research Findings There have been numerous clinical and scientific studies of Remifemin. The most recent (Osmers, et al; 2005), a randomized, multicenter, double-blind clinical trial, compared the efficacy and tolerability of Remifemin in the treatment of menopausal symptoms compared with placebo. A total of 304 women were randomly allocated to receive 40mg of Remifemin or matching placebo daily for 12 weeks. The results showed that women in the Remifemin group experienced a significant decrease in hot flashes. No significant adverse effects were reported. Conclusion Remifemin, a unique extract of black cohosh (Cimicifuga racemosa), is the most studied form of black cohosh, with more than 20 clinical trials and open scientific monitoring trials in physicians' practices. No significant drug interaction